You are here: Home » Current Affairs » Coronavirus » News
Business Standard

UK approves Pfizer-BioNTech Covid vaccine; to be available from next week

The U.K. had signaled it would move swiftly in approving a vaccine to protect its population, and doctors across the country were put on standby for a possible rollout

Topics
Coronavirus Vaccine | Coronavirus | Pfizer

James Paton & Naomi Kresge | Bloomberg 

Pfizer
Pfizer and BioNTech earlier this week sought regulatory clearance for their vaccine in the European Union.

The U.K. became the first western country to approve a Covid-19 vaccine, with its regulator clearing Inc. and BioNTech SE’s shot ahead of decisions in the U.S. and European Union.

The emergency authorisation clears the way for the deployment of a vaccine that’s expected to play a significant role in the global effort to halt the and its German partner said in November that the shot, relying on novel technology called messenger RNA, was 95% effective in a final analysis of clinical-trial data.

The vaccine will be available in Britain from next week, according to a government statement. The U.K. regulator, the Medicines and Healthcare Products Regulatory Agency, said on Wednesday that the vaccine “met its strict standards of safety, quality and effectiveness.”

The U.K. had signaled it would move swiftly in approving a vaccine to protect its population, and doctors across the country were put on standby for a possible rollout. For the government, it’s an opportunity to make up for missteps during the pandemic as Britain’s death toll nears 60,000.

ALSO READ: Coronavirus LIVE: UK approves Pfizer Covid vaccine for mass roll out

Regulators are facing pivotal decisions as companies including Pfizer, Moderna Inc. and the University of Oxford’s partner, AstraZeneca Plc, sprint ahead in a bid to deliver vaccines in record time.

EU Application

and BioNTech earlier this week sought regulatory clearance for their vaccine in the European Union, putting the shot on track for potential approval there before the end of the year. In the U.S., a Food and Drug Administration panel is set to meet on Dec. 10 to discuss the vaccine.

China has given authorisation to its three front-runners for emergency use. Russia cleared a vaccine known as Sputnik V in August, while a second inoculation was approved in October, even as the last stage of trials to establish safety and efficacy are still taking place.

The British government in late November invoked a special rule allowing its drug regulator to move ahead of the EU as the country prepares for the Brexit transition period to conclude at the end of this year.

The U.K. has ordered enough doses of the two-shot Pfizer-BioNTech vaccine to immunise 20 million people. The companies also have deals to supply hundreds of millions of shots to Europe, the U.S., Japan and elsewhere.

The Pfizer-BioNTech shot dashed to the head of the queue after delays to the trials of the AstraZeneca-Oxford vaccine, which has also shown promising signs in preliminary results of broad studies. The U.K. partners have faced questions after acknowledging that a lower dosage level that appeared more effective resulted from a manufacturing discrepancy.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, December 02 2020. 13:05 IST
RECOMMENDED FOR YOU